What Are The Benefits And Harms Of Belimumab For Patients With Systemic Lupus Erythematosus?: A Cochrane Review Summary With Commentary
Int J Rheum Dis. 2021;24(10):1331–3
Biologic therapies, particularly belimumab, show promising results in the clinical management of SLE.
Giovanni Iolascon provides a commentary to the published Cochrane Review “Belimumab for systemic lupus erythematosus”. Based on the Cochrane Systematic Review evidence, belimumab showed benefits in terms of modifying SLE disease activity and promoting GC sparing. While its safety profile remains unclear, due to the short-term duration of the trials included, future investigations of belimumab versus an active comparator should be an interesting topic for both research and clinical practice.
